Rain Therapeutics Announces Completion of Enrollment in Phase III MANTRA Trial for Milademetan in Liposarcoma

Rain Therapeuticsm, Inc. announced completion of enrollment in its Phase III MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.